{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:29:08Z","timestamp":1763458148904},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,29]]},"DOI":"10.7759\/cureus.25447","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T14:25:40Z","timestamp":1653834340000},"source":"Crossref","is-referenced-by-count":1,"title":["Azithromycin-Induced Liver Injury in an Asthma Exacerbation Patient With Autoimmune Features"],"prefix":"10.7759","author":[{"given":"Richard","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adesh","family":"Ramdass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112739","article-title":"Azithromycin: the first broad-spectrum therapeutic","volume":"207","author":"Firth A","year":"2020","unstructured":"Firth A, Prathapan P. Azithromycin: the first broad-spectrum therapeutic. Eur J Med Chem. 2020, 207:112739. 10.1016\/j.ejmech.2020.112739","journal-title":"Eur J Med Chem"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson PG","year":"2017","unstructured":"Gibson PG, Yang IA, Upham JW, et al.. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017, 390:659-68. 10.1016\/S0140-6736(17)31281-3","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.2005.50146.x","article-title":"Polymorphic ventricular tachycardia with a normal QT interval following azithromycin","volume":"28","author":"Kim MH","year":"2005","unstructured":"Kim MH, Berkowitz C, Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol. 2005, 28:1221-2. 10.1111\/j.1540-8159.2005.50146.x","journal-title":"Pacing Clin Electrophysiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(00)00724-5","article-title":"Hypersensitivity syndrome associated with azithromycin","volume":"110","author":"Cascaval RI","year":"2001","unstructured":"Cascaval RI, Lancaster DJ. Hypersensitivity syndrome associated with azithromycin. Am J Med. 2001, 110:330-1. 10.1016\/s0002-9343(00)00724-5","journal-title":"Am J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.652674","article-title":"Ototoxicity of non-aminoglycoside antibiotics","volume":"12","author":"Rybak LP","year":"2021","unstructured":"Rybak LP, Ramkumar V, Mukherjea D. Ototoxicity of non-aminoglycoside antibiotics. Front Neurol. 2021, 12:652674. 10.3389\/fneur.2021.652674","journal-title":"Front Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.07.054","article-title":"Clinical and histologic features of azithromycin-induced liver injury","volume":"13","author":"Martinez MA","year":"2015","unstructured":"Martinez MA, Vuppalanchi R, Fontana RJ, et al.. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol. 2015, 13:369-76.e3. 10.1016\/j.cgh.2014.07.054","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080687","article-title":"Azithromycin-induced liver injury","volume":"67","author":"Lockwood AM","year":"2010","unstructured":"Lockwood AM, Cole S, Rabinovich M. Azithromycin-induced liver injury. Am J Health Syst Pharm. 2010, 67:810-4. 10.2146\/ajhp080687","journal-title":"Am J Health Syst Pharm"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17856","article-title":"Azithromycin-induced liver injury in Legionnaires' disease","volume":"13","author":"Wong KM","year":"2021","unstructured":"Wong KM, Hosseinnejad K, Palaparty P, Ravakhah K. Azithromycin-induced liver injury in Legionnaires' disease. Cureus. 2021, 13:e17856. 10.7759\/cureus.17856","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009346","article-title":"Intrahepatic cholestasis of pregnancy or azithromycin-induced intrahepatic cholestasis: a case report","volume":"96","author":"Han B","year":"2017","unstructured":"Han B, Sheng Y, Wang L, Feng H, Hou X, Li Y. Intrahepatic cholestasis of pregnancy or azithromycin-induced intrahepatic cholestasis: a case report. Medicine (Baltimore). 2017, 96:e9346. 10.1097\/MD.0000000000009346","journal-title":"Medicine (Baltimore)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani N","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, et al.. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015, 148:1340-52.e7. 10.1053\/j.gastro.2015.03.006","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.131","article-title":"ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani NP","year":"2014","unstructured":"Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014, 109:950-66; quiz 967. 10.1038\/ajg.2014.131","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-013-0015-5","article-title":"Drug-induced liver injury throughout the drug development life cycle: where we have been, where we are now, and where we are headed. Perspectives of a clinical hepatologist","volume":"27","author":"Lewis JH","year":"2013","unstructured":"Lewis JH. Drug-induced liver injury throughout the drug development life cycle: where we have been, where we are now, and where we are headed. Perspectives of a clinical hepatologist. Pharm Med. 2013, 27:165-91. 10.1007\/s40290-013-0015-5","journal-title":"Pharm Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.07.001","article-title":"Drug-induced acute liver failure","volume":"17","author":"Lee WM","year":"2013","unstructured":"Lee WM. Drug-induced acute liver failure. Clin Liver Dis. 2013, 17:575-86, viii. 10.1016\/j.cld.2013.07.001","journal-title":"Clin Liver Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13458","article-title":"Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda","volume":"38","author":"Sebode M","year":"2018","unstructured":"Sebode M, Hartl J, Vergani D, Lohse AW. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver Int. 2018, 38:15-22. 10.1111\/liv.13458","journal-title":"Liver Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack CL","year":"2020","unstructured":"Mack CL, Adams D, Assis DN, et al.. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020, 72:671-722. 10.1002\/hep.31065","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619872408","article-title":"Clinical management of autoimmune hepatitis","volume":"7","author":"Pape S","year":"2019","unstructured":"Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. United European Gastroenterol J. 2019, 7:1156-63. 10.1177\/2050640619872408","journal-title":"United European Gastroenterol J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez F","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999, 31:929-38. 10.1016\/s0168-8278(99)80297-9","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-021-00759-z","article-title":"Factors associated with the antinuclear antibody (ANA) titer of systemic autoimmune rheumatic diseases in ANA-positive patients after treatment: a retrospective study","author":"Xiao Y","year":"2021","unstructured":"Xiao Y, Lin Y, Zhang Y, Wang J, Zeng Y. Factors associated with the antinuclear antibody (ANA) titer of systemic autoimmune rheumatic diseases in ANA-positive patients after treatment: a retrospective study. Clin Exp Med. 2021, 10.1007\/s10238-021-00759-z","journal-title":"Clin Exp Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/ar3271","article-title":"Risk factors for ANA positivity in healthy persons","volume":"13","author":"Li QZ","year":"2011","unstructured":"Li QZ, Karp DR, Quan J, et al.. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther. 2011, 13:R38. 10.1186\/ar3271","journal-title":"Arthritis Res Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2582-y","article-title":"Analyzing the mechanisms behind macrolide antibiotic-induced liver injury using quantitative systems toxicology modeling","volume":"36","author":"Woodhead JL","year":"2019","unstructured":"Woodhead JL, Yang K, Oldach D, et al.. Analyzing the mechanisms behind macrolide antibiotic-induced liver injury using quantitative systems toxicology modeling. Pharm Res. 2019, 36:48. 10.1007\/s11095-019-2582-y","journal-title":"Pharm Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bj\u00f6rnsson E","year":"2012","unstructured":"Bj\u00f6rnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012, 56:374-80. 10.1016\/j.jhep.2011.07.023","journal-title":"J Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/92852-azithromycin-induced-liver-injury-in-an-asthma-exacerbation-patient-with-autoimmune-features","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:10Z","timestamp":1707507370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/92852-azithromycin-induced-liver-injury-in-an-asthma-exacerbation-patient-with-autoimmune-features"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,29]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.25447","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,29]]}}}